Table 1 Baseline characteristics of 66 subjects with PAH on inhaled prostacyclin
Characteristic | Baseline (n = 66) |
|---|---|
Age, mean (range), yr | 49 (18 – 74) |
Male : Female, n (%) | 15 (23) : 51 (77) |
White* | 58 (88) |
PAH etiology, n (%) | |
Idiopathic/heritable | 33 (50) |
Collagen vascular disease | 13 (20) |
Congenital heart disease | 17 (26) |
HIV | 3 (5) |
Background PAH therapy, n (%) | |
Endothelin receptor antagonist | 56 (85) |
Phosphodiesterase-5 inhibitor | 46 (70) |
Both | 39 (59) |
None | 3 (5) |
WHO functional class, n (%) | |
II | 38 (58) |
III | 28 (42) |
6-minute walk distance, mean ± SD, m | 395 ± 79 |
Borg dypnea score, mean ± SD | 3.4 ± 2.1 |
Iloprost dose, n (%) | |
2.5 μg | 4 (6) |
5.0 μg | 62 (94) |
Iloprost frequency | |
< 6 times per day | 25 (38) |
≥ 6 times per day | 41 (62) |